Back to News
Market Impact: 0.35
Edwards' PASCAL System Improves Outcomes And Quality Of Life In Tricuspid Valve Disease Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Edwards Lifesciences reported positive results from its CLASP II TR trial: the PASCAL transcatheter valve repair system outperformed medical therapy alone in patients with tricuspid regurgitation. The provided article excerpt includes no numerical efficacy results or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
EW0.65
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge